PUBLISHER: TechNavio | PRODUCT CODE: 1783905
PUBLISHER: TechNavio | PRODUCT CODE: 1783905
The generative AI in clinical trial market is forecasted to grow by USD 572.7 mn during 2024-2029, accelerating at a CAGR of 30.8% during the forecast period. The report on the generative AI in clinical trial market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by overarching imperative to reduce clinical development costs and timelines, management of increasing trial complexity and proliferation of multimodal data, and rapid technological maturation and strategic cross-industry collaborations.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 28.2% |
CAGR | 30.8% |
Incremental Value | $572.7 mn |
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's generative AI in clinical trial market is segmented as below:
By Deployment
By Application
By End-user
By Geographical Landscape
This study identifies the ascendance of domain-specific and multimodal generative models as one of the prime reasons driving the generative AI in clinical trial market growth during the next few years. Also, proliferation of ai-as-a-service ecosystem and deep platform integration and evolutionary shift from pure automation to human augmentation and novel discovery will lead to sizable demand in the market.
The report on the generative AI in clinical trial market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading generative AI in clinical trial market vendors that include A.I. VALI Inc., Acclinate Inc., AiCure, Antidote Technologies Inc., Claritrics Inc., ConcertAI Inc., Deep 6 AI Inc., Exscientia plc, Innoplexus, Intelligencia Inc., Median Technologies SA, Medidata, Opyl Ltd, Owkin Inc., SiteRx Inc., Tempus Labs Inc., Trials.ai, and Unlearn.ai Inc. Also, the generative AI in clinical trial market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: